These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12426560)

  • 1. T cells require TRAIL for optimal graft-versus-tumor activity.
    Schmaltz C; Alpdogan O; Kappel BJ; Muriglan SJ; Rotolo JA; Ongchin J; Willis LM; Greenberg AS; Eng JM; Crawford JM; Murphy GF; Yagita H; Walczak H; Peschon JJ; van den Brink MR
    Nat Med; 2002 Dec; 8(12):1433-7. PubMed ID: 12426560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors.
    Tateishi K; Ohta M; Guleng B; Kanai F; Tanaka Y; Asaoka Y; Jazag A; Imamura J; Imamura T; Ijichi H; Ikenoue T; Kawakami T; Fukushima Y; Washida M; Sata M; Miyagishi M; Taira K; Yoshida H; Kawabe T; Omata M
    Int J Cancer; 2006 May; 118(9):2237-46. PubMed ID: 16331624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
    Ito M; Shizuru JA
    Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.
    Ghosh A; Dogan Y; Moroz M; Holland AM; Yim NL; Rao UK; Young LF; Tannenbaum D; Masih D; Velardi E; Tsai JJ; Jenq RR; Penack O; Hanash AM; Smith OM; Piersanti K; Lezcano C; Murphy GF; Liu C; Palomba ML; Sauer MG; Sadelain M; Ponomarev V; van den Brink MR
    J Clin Invest; 2013 Jun; 123(6):2654-62. PubMed ID: 23676461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
    Ramirez-Montagut T; Chow A; Kochman AA; Smith OM; Suh D; Sindhi H; Lu S; Borsotti C; Grubin J; Patel N; Terwey TH; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
    J Immunol; 2007 Aug; 179(3):1669-80. PubMed ID: 17641033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
    Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
    Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
    Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
    J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
    Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
    Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.
    Na IK; Lu SX; Yim NL; Goldberg GL; Tsai J; Rao U; Smith OM; King CG; Suh D; Hirschhorn-Cymerman D; Palomba L; Penack O; Holland AM; Jenq RR; Ghosh A; Tran H; Merghoub T; Liu C; Sempowski GD; Ventevogel M; Beauchemin N; van den Brink MR
    J Clin Invest; 2010 Jan; 120(1):343-56. PubMed ID: 19955659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies.
    Snell V; Clodi K; Zhao S; Goodwin R; Thomas EK; Morris SW; Kadin ME; Cabanillas F; Andreeff M; Younes A
    Br J Haematol; 1997 Dec; 99(3):618-24. PubMed ID: 9401075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
    Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K
    Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunological mechanisms of graft versus tumor effect].
    Ine S; Yamada M; Miyamura K; Sasaki T
    Nihon Rinsho; 2003 Sep; 61(9):1495-502. PubMed ID: 14515715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytolytic pathways in haematopoietic stem-cell transplantation.
    van den Brink MR; Burakoff SJ
    Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.
    Mundhada S; Shaw J; Mori S; Savary CA; Mullen CA
    Leuk Lymphoma; 2005 Apr; 46(4):571-80. PubMed ID: 16019486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.